Comparative Efficacy, Safety, and Tolerability of Atogepant and Erenumab: Indirect Treatment Comparison of the TEMPLE and HER-MES Head-to-head Trials (P10-15.002)

Key Points

• The study aims to compare the efficacy, safety, and tolerability of atogepant and erenumab in adults with migraine.
• Conducted an indirect treatment comparison between the TEMPLE and HER-MES trials.
• Focused on adult participants diagnosed with migraine.
• Atogepant demonstrated superior efficacy compared to erenumab in reducing migraine frequency.
• Both treatments showed a similar safety profile, with tolerability rated as acceptable in the majority of participants.